SRR1516068
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.440
- SPERMATOGENESIS+0.320
- FATTY_ACID_METABOLISM+0.300
- PANCREAS_BETA_CELLS+0.270
- MITOTIC_SPINDLE+0.250
- MYC_TARGETS_V2+0.230
- OXIDATIVE_PHOSPHORYLATION+0.220
- PEROXISOME+0.210
- MYC_TARGETS_V1+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.530
- IL6_JAK_STAT3_SIGNALING-0.480
- TNFA_SIGNALING_VIA_NFKB-0.460
- COAGULATION-0.440
- INFLAMMATORY_RESPONSE-0.440
- COMPLEMENT-0.410
- PROTEIN_SECRETION-0.410
- ANGIOGENESIS-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202476 | — | — | 0.903 |
| 2 | SRR8943022 | — | — | 0.902 |
| 3 | SRR12202497 | — | — | 0.901 |
| 4 | R55 | — | — | 0.896 |
| 5 | TCGA-GV-A40G-01A-11R-A23N-07 | — | — | 0.894 |
| 6 | SRR26320088 | — | — | 0.891 |
| 7 | C3L-01285 | — | cohortSQ2 | 0.891 |
| 8 | SRR23303756 | — | — | 0.882 |
| 9 | SRR1516065 | — | — | 0.881 |
| 10 | R115 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |